Yes. A phase I-II trial of IMRT dose-escalation (50-60 Gy) with concurrent gemcitabine in 50 pts with unresectable PCA found dose-limiting toxicities in 11 pts, including duodenal bleed (3 pts) and perforation (1 pt). The recommended dose was 55 Gy, with an estimated 24% rate of dose-limiting toxicity (Ben-JosefE et al., IJROBP 2012). Single institution data from MDACC (KrishnanS et al., IJROBP 2016) found improved survival (MS 17.8 vs. 15 mos, p = 0.03) in pts with BED >70 Gy₁₀ compared to biological effective dose (BED) ≤70 Gy₁₀. No increased toxicity was seen in the higher-dose group. An example of BED 70 Gy₁₀ would be 57.27 Gy in 25 fx.